FY2026 EPS Estimates for Savara Decreased by Lifesci Capital

Key Points

• Lifesci Capital cut its FY2026 EPS estimate for Savara to ($0.52) from ($0.48), below the consensus of ($0.45), and projects Q4 FY2026 EPS of ($0.14).
• Analyst coverage is mixed, but MarketBeat shows a consensus rating of Moderate Buy with a $9.00 target while individual notes range from Strong Buy/Buy to Hold/Sell.
• Savara shares trade around $5.78 with a $1.18B market cap and a 52‑week range of $1.89–$7.01; the company recently missed quarterly EPS (‑$0.13 vs. ‑$0.12) and institutions own about 87.9% of the stock.

Savara Inc. (NASDAQ:SVRA - Free Report) - Lifesci Capital cut their FY2026 EPS estimates for shares of Savara in a research report issued on Thursday, April 16th. Lifesci Capital analyst F. Brisebois now forecasts that the company will post earnings per share of ($0.52) for the year, down from their previous estimate of ($0.48). The consensus estimate for Savara's current full-year earnings is ($0.45) per share. Lifesci Capital also issued estimates for Savara's Q4 2026 earnings at ($0.14) EPS.

Other analysts have also issued reports about the stock. Wall Street Zen lowered shares of Savara from a "hold" rating to a "sell" rating in a research note on Saturday, March 14th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Savara in a report on Thursday, January 22nd. HC Wainwright restated a "buy" rating on shares of Savara in a research note on Monday, March 16th. Guggenheim reaffirmed a "buy" rating on shares of Savara in a research report on Tuesday, December 23rd. Finally, UBS Group set a $10.00 price objective on Savara in a research note on Tuesday, December 23rd. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Savara has a consensus rating of "Moderate Buy" and a consensus target price of $9.00.

Savara Price Performance

SVRA opened at $5.78 on Monday. The business has a fifty day moving average of $5.53 and a 200 day moving average of $5.31. The stock has a market cap of $1.18 billion, a P/E ratio of -10.91 and a beta of 0.32. The company has a quick ratio of 11.85, a current ratio of 11.85 and a debt-to-equity ratio of 0.15. Savara has a 52-week low of $1.89 and a 52-week high of $7.01.

Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings data on Friday, March 13th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01).

Institutional Investors Weigh In On Savara

Large investors have recently modified their holdings of the business. Swedbank AB bought a new position in shares of Savara during the third quarter valued at approximately $1,964,000. Rosalind Advisors Inc. boosted its position in Savara by 50.7% during the 3rd quarter. Rosalind Advisors Inc. now owns 4,000,000 shares of the company's stock valued at $14,280,000 after acquiring an additional 1,345,056 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Savara in the 3rd quarter valued at $96,000. Sivia Capital Partners LLC raised its position in shares of Savara by 16.9% in the 3rd quarter. Sivia Capital Partners LLC now owns 48,500 shares of the company's stock worth $173,000 after acquiring an additional 7,000 shares in the last quarter. Finally, Voya Investment Management LLC lifted its stake in shares of Savara by 7.5% during the 3rd quarter. Voya Investment Management LLC now owns 856,600 shares of the company's stock worth $3,058,000 after purchasing an additional 59,482 shares during the last quarter. Institutional investors own 87.93% of the company's stock.

Savara Company Profile

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.